Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis International Small Cap Value ETF (AVDV) vs BioNano Genomics Inc (BNGO) Price & Performance

Avantis International Small Cap Value ETFTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Avantis International Small Cap Value ETF vs BioNano Genomics Inc — how do they compare? Avantis International Small Cap Value ETF trades at $110.25, while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

AVDVBNGO
Sector
Sector/ThematicHealth
52-Week High
$110.40$4.92
52-Week Low
$83.89$1.06
Market Cap
$13.66M
Enterprise Value
$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis International Small Cap Value ETF

AVDV trades at $110.27, up 0.74% today, with a bullish technical signal from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies delivering 35% gains and dividends. The fund focuses on cheap, profitable small companies in developed markets outside the U.S., benefiting from diversification and value exposure.

The outlook remains positive due to historical outperformance and dividend yield, but risks include overbought technicals and reliance on global economic stability. Investors should weigh the fund's value approach against potential volatility in international small caps, with support near $108 providing a cushion for pullbacks.

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

About Avantis International Small Cap Value ETF

AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.

Read more on AVDV

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO